Parkinson’s Treatment Report

www.ParkinsonsTreatmentReport.com

Phase 1

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03976349?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F23%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson’s Disease
Interventions:   Drug: BIIB094;   Drug: Placebo
Sponsors:   Biogen;   Ionis Pharmaceuticals, Inc.
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03976349

FIRST POSTED:
Thu, 06 Jun 2019 12:00:00 EDT

LAST UPDATE POSTED:
06/06/19 07:37AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03976349?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F23%2F2019&lupd_d=14&sort=nwst

TSPO-PET for Neuroinflammation in Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03457493?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=04%2F13%2F2020&lupd_d=14&sort=nwst

STUDY TITLE:
TSPO-PET for Neuroinflammation in Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Intervention:   Drug: DPA-714-PET/MRI
Sponsor:   University of Alabama at Birmingham
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03457493

FIRST POSTED:
Wed, 07 Mar 2018 12:00:00 EST

LAST UPDATE POSTED:
04/27/20 09:21AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03457493?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=04%2F13%2F2020&lupd_d=14&sort=nwst

Brain Bioenergetics in Parkinson’s Disease and Response to Repeated Oral UDCA Treatment

https://clinicaltrials.gov/ct2/show/NCT02967250?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=10%2F18%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Brain Bioenergetics in Parkinson’s Disease and Response to Repeated Oral UDCA Treatment

DESCRIPTION:
Condition:   Parkinson Disease
Intervention:   Drug: ursodeoxycholic acid
Sponsor:   University of Minnesota
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT02967250

FIRST POSTED:
Fri, 18 Nov 2016 12:00:00 EST

LAST UPDATE POSTED:
11/01/19 08:39AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT02967250?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=10%2F18%2F2019&lupd_d=14&sort=nwst

Transplantation of Neural Stem Cell-Derived Neurons for Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03309514?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F12%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Transplantation of Neural Stem Cell-Derived Neurons for Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson’s Disease
Intervention:   Biological: Intracerebral microinjections
Sponsor:   NeuroGeneration
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03309514

FIRST POSTED:
Fri, 13 Oct 2017 12:00:00 EDT

LAST UPDATE POSTED:
09/26/19 07:45AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03309514?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F12%2F2019&lupd_d=14&sort=nwst

Study to Evaluate DNL151 in Subjects With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT04056689?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=07%2F31%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Study to Evaluate DNL151 in Subjects With Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: DNL151 low dose;   Drug: DNL151 high dose;   Drug: Placebo
Sponsor:   Denali Therapeutics Inc.
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04056689

FIRST POSTED:
Wed, 14 Aug 2019 12:00:00 EDT

LAST UPDATE POSTED:
08/14/19 07:51AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04056689?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=07%2F31%2F2019&lupd_d=14&sort=nwst

A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson’s Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214

https://clinicaltrials.gov/ct2/show/NCT02579473?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F04%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson’s Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214

DESCRIPTION:
Condition:   Parkinson’s Disease
Intervention:   Drug: SER-214
Sponsor:   Serina Therapeutics
Active, not recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT02579473

FIRST POSTED:
Mon, 19 Oct 2015 12:00:00 EDT

LAST UPDATE POSTED:
09/18/19 07:46AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT02579473?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F04%2F2019&lupd_d=14&sort=nwst

Open-label Investigation of the Safety and Clinical Effects of NTCELL in Patients With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT01734733?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F02%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Open-label Investigation of the Safety and Clinical Effects of NTCELL in Patients With Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson’s Disease
Intervention:   Other: NTCELL
Sponsor:   Living Cell Technologies
Active, not recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT01734733

FIRST POSTED:
Wed, 28 Nov 2012 12:00:00 EST

LAST UPDATE POSTED:
09/16/19 07:45AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT01734733?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=09%2F02%2F2019&lupd_d=14&sort=nwst

Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03407378?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=08%2F05%2F2019&lupd_d=14&sort=nwst

A Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients With Parkinson’s Disease

STUDY TITLE:
A Study to Investigate a New Treatment in Patients With Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: IPT803;   Genetic: Optional pharmacogenetic assessment;   Other: Questionnaires;   Other: Optional Blood-Oxygen-level Dependent functionalMRI;   Other: Motor Assessments before taking regular PD treatment;   Other: Motor Assessments on regular PD treatment
Sponsor:   Tools4Patient
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03407378

FIRST POSTED:
Tue, 23 Jan 2018 12:00:00 EST

LAST UPDATE POSTED:
08/19/19 10:02AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03407378?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=08%2F05%2F2019&lupd_d=14&sort=nwst

Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03720418?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=08%2F16%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: OXB-102;   Other: Imitation Surgical Procedure (ISP)
Sponsors:   Axovant Sciences Ltd.;   Oxford BioMedica
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03720418

FIRST POSTED:
Thu, 25 Oct 2018 12:00:00 EDT

LAST UPDATE POSTED:
08/30/19 09:00AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03720418?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=08%2F16%2F2019&lupd_d=14&sort=nwst

Study of UB-312 in Healthy Participants and Parkinson’s Disease Patients

https://clinicaltrials.gov/ct2/show/NCT04075318?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=08%2F16%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Study of UB-312 in Healthy Participants and Parkinson’s Disease Patients

DESCRIPTION:
Conditions:   Parkinson Disease;   Parkinsonism
Interventions:   Biological: UB-312;   Biological: Placebo
Sponsors:   United Neuroscience Ltd.;   Centre for Human Drug Research, Netherlands;   Worldwide Clinical Trials
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04075318

FIRST POSTED:
Fri, 30 Aug 2019 12:00:00 EDT

LAST UPDATE POSTED:
08/30/19 09:00AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04075318?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=08%2F16%2F2019&lupd_d=14&sort=nwst

Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03295786?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=06%2F21%2F2019&lupd_d=14&sort=nwst

Phase 1-2, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Via an Investigational Drug Delivery System to Patients With Parkinson’s Disease

STUDY TITLE:
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson’s Disease

DESCRIPTION:
Conditions:   Parkinson Disease;   Movement Disorders;   Neurodegenerative Diseases;   Nervous System Diseases;   Brain Diseases
Interventions:   Drug: Cerebral Dopamine Neurotrophic Factor;   Device: Renishaw Drug Delivery System
Sponsors:   Herantis Pharma Plc.;   Renishaw plc.
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03295786

FIRST POSTED:
Thu, 28 Sep 2017 12:00:00 EDT

LAST UPDATE POSTED:
07/05/19 07:10AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03295786?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=06%2F21%2F2019&lupd_d=14&sort=nwst

Dose Escalation Study of Cu(II)ATSM in Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03204929?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=06%2F11%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Dose Escalation Study of Cu(II)ATSM in Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Intervention:   Drug: Cu(II)ATSM
Sponsor:   Collaborative Medicinal Development Pty Limited
Active, not recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03204929

FIRST POSTED:
Sun, 02 Jul 2017 12:00:00 EDT

LAST UPDATE POSTED:
06/25/19 06:51AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03204929?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=06%2F11%2F2019&lupd_d=14&sort=nwst

Study to Evaluate DNL201 in Subjects With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03710707?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F22%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Study to Evaluate DNL201 in Subjects With Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: DNL201 low dose;   Drug: DNL201 high dose;   Drug: Placebo
Sponsor:   Denali Therapeutics Inc.
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03710707

FIRST POSTED:
Thu, 18 Oct 2018 12:00:00 EDT

LAST UPDATE POSTED:
06/05/19 07:44AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03710707?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F22%2F2019&lupd_d=14&sort=nwst

Chronic Effects of DBS in Parkinson’s Disease and Dystonia

https://clinicaltrials.gov/ct2/show/NCT01934296?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F22%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Chronic Effects of DBS in Parkinson’s Disease and Dystonia

DESCRIPTION:
Conditions:   Parkinson’s Disease;   Isolated Dystonia
Intervention:   Device: Activa PC+S
Sponsors:   University of California, San Francisco;   Medtronic
Active, not recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT01934296

FIRST POSTED:
Wed, 04 Sep 2013 12:00:00 EDT

LAST UPDATE POSTED:
06/05/19 07:44AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT01934296?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F22%2F2019&lupd_d=14&sort=nwst

Modulation of Gut Microbiota by Rifaximin in PD Patients

https://clinicaltrials.gov/ct2/show/NCT03958708?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F08%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Modulation of Gut Microbiota by Rifaximin in PD Patients

DESCRIPTION:
Conditions:   Parkinson Disease;   Inflammation
Intervention:   Drug: Rifaximin 550 MG
Sponsor:   Taipei Medical University Shuang Ho Hospital
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03958708

FIRST POSTED:
Wed, 22 May 2019 12:00:00 EDT

LAST UPDATE POSTED:
05/22/19 07:42AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03958708?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F08%2F2019&lupd_d=14&sort=nwst

A Phase 1 Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects

https://clinicaltrials.gov/ct2/show/NCT03954600?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F03%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Phase 1 Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects

DESCRIPTION:
Condition:   Healthy Volunteers
Interventions:   Drug: NPT520-34 (125 mg);   Drug: Placebos (125 mg)
Sponsors:   Neuropore Therapies Inc.;   Celerion
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03954600

FIRST POSTED:
Fri, 17 May 2019 12:00:00 EDT

LAST UPDATE POSTED:
05/17/19 07:09AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03954600?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F03%2F2019&lupd_d=14&sort=nwst

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson’s Disease

https://clinicaltrials.gov/ct2/show/NCT03716570?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F01%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson’s Disease

DESCRIPTION:
Condition:   Parkinson’s Disease
Interventions:   Drug: BIIB054;   Drug: Placebo
Sponsor:   Biogen
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03716570

FIRST POSTED:
Tue, 23 Oct 2018 12:00:00 EDT

LAST UPDATE POSTED:
05/15/19 07:32AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03716570?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=05%2F01%2F2019&lupd_d=14&sort=nwst

Single Ascending Dose Study of MEDI1341 in Healthy Volunteers

https://clinicaltrials.gov/ct2/show/NCT03272165?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=04%2F29%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Single Ascending Dose Study of MEDI1341 in Healthy Volunteers

DESCRIPTION:
Condition:   Parkinson’s Disease
Interventions:   Drug: MEDI1341;   Drug: Placebo
Sponsors:   AstraZeneca;   Covance;   MMS Holdings, Inc;   Catalent
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03272165

FIRST POSTED:
Tue, 05 Sep 2017 12:00:00 EDT

LAST UPDATE POSTED:
05/13/19 07:43AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03272165?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=04%2F29%2F2019&lupd_d=14&sort=nwst

Back to top